VTAK
Catheter Precision·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
Bearish Engulfing
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VTAK
Catheter Precision, Inc.
A commercial grade medical device company
Healthcare Equipment and Supplies
--
12/28/2020
American Stock Exchange
22
12-31
Common stock
1670 Highway 160 West – Suite 205, Fort Mill, South Carolina 29708
--
Catheter Precision, Inc., was incorporated in Delaware in July 2018 and was previously incorporated in California on September 4, 2002. The company is a commercial-stage medical device company utilizing advanced excimer laser-based platforms for the treatment of vascular and skin diseases. The company believes that products improve patients' quality of life by restoring arterial blood flow and clearing chronic skin conditions. DABRA is approved by the US Food and Drug Administration (FDA) as a minimally invasive endovascular treatment tool for vascular blockages caused by lower extremity vascular disease, including peripheral arterial disease or PAD, which often occurs in the legs. Ra Medical Systems intends to pursue uses for DABRA, including seeking regulatory approval for the use of DABRA as a tool for the treatment of vascular blockages associated with coronary artery disease or CAD, in-stent restenosis, venous and arterial blockages, or venous or arterial blockages. The DABRA laser system is based on the same core technology and uses an excimer laser similar to PharOS, a medical device that the company has been marketing as a tool for the treatment of proliferative skin conditions since October 2004. Pharos is designed for the treatment of inflammatory skin conditions and is approved by the FDA as a tool for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. Since both DABRA and PHAROS are based on their core excimer laser technology platforms and deploy similar mechanisms of action, they benefit from economies of scale in product development, manufacturing, quality assurance and distribution.
Company Financials
EPS
VTAK has released its 2024 Q2 earnings. EPS was reported at -5.57, versus the expected -2.63, missing expectations. The chart below visualizes how VTAK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VTAK has released its 2025 Q3 earnings report, with revenue of 226.00K, reflecting a YoY change of 135.42%, and net profit of -2.34M, showing a YoY change of 43.11%. The Sankey diagram below clearly presents VTAK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
